To define the role the PI3K/AKT signalling pathway affected by SLC1A3 in the regulation of gastric cancer progression, the glucose metabolism and malignant biological behaviours of cells overexpressing SLC1A3 treated with LY294002 (an inhibitor of PI3K/AKT) were explored. The gene discussed is SLC1A3; the disease is gastric cancer.